Dr Reddys surges 5% as Sputnik V gets expert panel nod for emergency use business-standard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from business-standard.com Daily Mail and Mail on Sunday newspapers.
Story
Panacea Biotec share rises 20% on pact to make 100 million doses of Sputnik V vaccine per year
Share of the pharma firm rose 19.99% to Rs 220.85 against previous close of Rs 184.40 on BSE. The stock opened with a gain of 15.68% at Rs 212.90
BusinessToday.In | April 6, 2021 | Updated 10:40 IST
Panacea Biotec stock is trading higher than 5 day, 20 day, 50 day, 100 day and 200 day moving averages.
Panacea Biotec share rose 20% today after the drug maker said it has inked pact with Russian Direct Investment Fund (RDIF) to produce 100 million doses per year of the Sputnik V COVID-19 vaccine in India. Share of the pharma firm rose 19.99% to Rs 220.85 against previous close of Rs 184.40 on BSE.
Loading the player.
Rashi Bisaria | April 6, 2021
COVID-19 vaccination: Uddhav Thackeray asks PM Modi to reduce eligible age to 25 yrsMaharashtra Chief Minister Uddhav Thackeray has written a letter to Prime Minister Narendra Modi asking to reduce the age for getting COVID-19 vaccination to 25 years. Saying that the second wave of the coronavirus is much stronger than the first wave in the state, Thackeray said Maharashtra is taking up vaccination at a rapid pace and is the number 1 state in the country in terms of COVID-19 vaccine doses administered.
Meesho becomes latest entrant to Indian unicorn club with $300 million fundraiseIndian social commerce platform Meesho has entered the unicorn club after raising $300 million in the latest round of funding. The Series E funding round, led by SoftBank Group s Vision Fund 2, saw the valuation of the Bengaluru-based start-up rise to $2.1 billion from around $700 million in 2019.
COVID-19: Panacea Biotec to produce 100 million doses of Sputnik V in India annually
Production of Sputnik V at Panacea Biotec sites will help facilitate global supply of Sputnik V to international partners of RDIF.
BusinessToday.In | April 5, 2021 | Updated 21:34 IST
Panacea Biotec MD Rajesh Jain said the company will produce Sputnik V in its internationally accredited facilities.
Panacea Biotec on Monday said it has entered into an agreement with the Russian Direct Investment Fund (RDIF) to produce 100 million doses of COVID-19 vaccine Sputnik V in India annually.
Production of Sputnik V at Panacea Biotec sites will help facilitate global supply of Sputnik V to international partners of RDIF, the New-Delhi based company said in a release. Panacea Biotec has production facilities at Baddi (Himachal Pradesh), Lalru (Punjab) and Delhi.
COVID-19: Panacea Biotec to produce 100 million doses of Sputnik V in India annually businesstoday.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesstoday.in Daily Mail and Mail on Sunday newspapers.